a)Started with 100 mg, maximum 200 mg. Dose modifications: In case of peripheral neuropathy, thalidomide dose was reduced by 50% and bortezomib was reduced to 1 mg/m2. In case of renal impairment, melphalan dose was reduced by 25% if Cr clearance was <30 mL/min. For lenolidomide, the dose adjustments were: 10 mg for Cr clearance of <30 mL/min, 15 mg for Cr clearance <30–60 mL/min and 5 mg for patients on hemodialysis. The treatment response criteria was as defined by IMWG uniform response criteria [22].
Abbreviations: PO,